US FDA qualifies first AI tool to help speed liver disease drug development

FILE PHOTO: The corporate logo of the U.S. Food and Drug Administration (FDA) is shown in Silver Spring, Maryland, November 4, 2009. REUTERS/Jason Reed/File Photo

Dec 8 (Reuters) - The U.S. Food and Drug Administration has qualified the first artificial intelligence tool designed to help doctors assess a severe form of fatty liver disease in drug trials, the agency said on Monday.

Now, the tool will be publicly available to be used in any drug development program for the qualified context of use.